JP2017514483A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514483A5
JP2017514483A5 JP2016565257A JP2016565257A JP2017514483A5 JP 2017514483 A5 JP2017514483 A5 JP 2017514483A5 JP 2016565257 A JP2016565257 A JP 2016565257A JP 2016565257 A JP2016565257 A JP 2016565257A JP 2017514483 A5 JP2017514483 A5 JP 2017514483A5
Authority
JP
Japan
Prior art keywords
adenovirus
genome
albumin binding
protein
adenoviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565257A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514483A (ja
JP6639412B2 (ja
Filing date
Publication date
Priority claimed from EP14382162.7A external-priority patent/EP2940128A1/en
Application filed filed Critical
Publication of JP2017514483A publication Critical patent/JP2017514483A/ja
Publication of JP2017514483A5 publication Critical patent/JP2017514483A5/ja
Application granted granted Critical
Publication of JP6639412B2 publication Critical patent/JP6639412B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565257A 2014-04-30 2015-04-30 アルブミン結合部分を含んでなるアデノウイルス Active JP6639412B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382162.7A EP2940128A1 (en) 2014-04-30 2014-04-30 Adenovirus comprising an albumin-binding moiety
EP14382162.7 2014-04-30
PCT/EP2015/059593 WO2015166082A1 (en) 2014-04-30 2015-04-30 Adenovirus comprising an albumin-binding moiety

Publications (3)

Publication Number Publication Date
JP2017514483A JP2017514483A (ja) 2017-06-08
JP2017514483A5 true JP2017514483A5 (enExample) 2018-06-14
JP6639412B2 JP6639412B2 (ja) 2020-02-05

Family

ID=50774820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565257A Active JP6639412B2 (ja) 2014-04-30 2015-04-30 アルブミン結合部分を含んでなるアデノウイルス

Country Status (12)

Country Link
US (3) US10604549B2 (enExample)
EP (2) EP2940128A1 (enExample)
JP (1) JP6639412B2 (enExample)
KR (1) KR102628234B1 (enExample)
CN (1) CN106471125B (enExample)
AU (1) AU2015254535B2 (enExample)
BR (1) BR112016025297B1 (enExample)
CA (1) CA2946650C (enExample)
IL (1) IL248590B (enExample)
MX (1) MX381286B (enExample)
RU (1) RU2711371C2 (enExample)
WO (1) WO2015166082A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
US11077199B2 (en) 2017-08-09 2021-08-03 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
US20200330581A1 (en) * 2017-10-09 2020-10-22 Keith Black Oncolytic cancer immunotherapies and methods of use
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN119955743A (zh) * 2018-09-10 2025-05-09 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
EP3906038A4 (en) 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS
EP3911671A1 (en) 2019-04-29 2021-11-24 Mayo Foundation for Medical Education and Research Multivalent pd-l1 binding compounds for treating cancer
CA3149478A1 (en) 2019-08-05 2021-02-11 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
CN116271066A (zh) * 2021-12-13 2023-06-23 康希诺生物股份公司 一种重组腺病毒载体疫苗吸入给药递送系统
CN114159556B (zh) * 2021-12-14 2023-06-16 中国人民解放军军事科学院军事医学研究院 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体
KR20230095830A (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
WO2023120762A1 (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
EP4602078A2 (en) 2022-10-11 2025-08-20 Yale University Compositions and methods of using cell-penetrating antibodies
CN115624524B (zh) * 2022-10-25 2023-10-27 中国医科大学附属第一医院 Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO2001045746A2 (en) * 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1284294A4 (en) 2000-05-26 2004-10-13 Sumitomo Pharma RECOMBINANT ADENOVIRUS WITH REDUCED SIDE EFFECTS (12/05/01)
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
WO2007050128A2 (en) * 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
US20090074810A1 (en) 2006-04-28 2009-03-19 The Trustees Of The University Of Pennsylvania Modified Adenovirus Hexon Protein and Uses Thereof
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
CN101781636A (zh) 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
CN102844329B (zh) 2010-04-14 2016-01-20 财团法人牧岩生命工学研究所 分离自猿腺病毒血清型19的六邻体、其高变区和使用其的嵌合型腺病毒
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety

Similar Documents

Publication Publication Date Title
JP2017514483A5 (enExample)
RU2016146664A (ru) Аденовирус, содержащий альбумин-связывающий участок
JP5075839B2 (ja) 癌の処置のための腫瘍崩壊性アデノウイルス
ES2167365T5 (es) Vectores adenovirales de origen animal y utilizacion en terapia genica.
Raty et al. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications
ES2466415T3 (es) Construcción de recombinante de adenovirus oncolítico que expresa específicamente el factor inmunomodulador GM-CSF en células tumorales y usos del mismo
Yang et al. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy
JP2014516536A5 (enExample)
JP2015057052A5 (enExample)
Xiao et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo
Yokoda et al. Oncolytic virotherapy in upper gastrointestinal tract cancers
JP2022500013A (ja) グリコーゲンシンターゼキナーゼ−3(gsk3)のコード領域を含む複製能力ある組換えウイルス及び異常細胞を殺す方法
NZ537631A (en) Oncolytic virus replicating selectively in tumor cells
Sutter et al. Gene therapy for gastric cancer: is it promising?
JP2021500880A5 (enExample)
Ulasov et al. Oncolytic adenoviruses: a thorny path to glioma cure
Lundstrom Application of viruses for gene therapy and vaccine development
Yao et al. Current targeting strategies for adenovirus vectors in cancer gene therapy
JP2004505633A (ja) アデノウイルスe1b−55k単一アミノ酸変異体および使用方法
JP2013531681A5 (enExample)
Davis et al. Application of oncolytic viruses for cure of colorectal cancer
Curiel et al. Applications of viruses for cancer therapy
JP2022553870A (ja) 複製促進腫瘍溶解性アデノウイルス
Alemany Molecular design of oncolytic adenoviruses
Garcia-Aragoncillo et al. Design of virotherapy for effective tumor treatment